SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

The December 2023 quarter revenue stood at Rs. 1616.99 millions, up 6.13% as compared to Rs. 1523.57 millions during the corresponding quarter last year.The Company's Net profit for the December 2023 quarter have declined marginally to Rs. 157.00  millions as against Rs. 222.83 millions reported during the corresponding quarter ended.Operating profit for the quarter ended December 2023 decreased to 263.99 millions as compared to 338.15 millions of corresponding quarter ended December 2022.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202312 202212 % Var 202312 202212 % Var 202303 202203 % Var
Sales 1616.99 1523.57 6.13 4676.46 4303.51 8.67 6167.34 5201.35 18.57
Other Income 28.70 30.19 -4.94 52.31 44.92 16.45 43.20 27.62 56.41
PBIDT 263.99 338.15 -21.93 727.44 863.36 -15.74 1269.82 1079.38 17.64
Interest 25.56 11.88 115.15 38.38 18.19 111.00 24.14 64.07 -62.32
PBDT 238.43 326.27 -26.92 371.52 845.17 -56.04 1245.68 1015.31 22.69
Depreciation 35.03 30.59 14.51 103.31 89.16 15.87 123.42 100.80 22.44
PBT 203.40 295.68 -31.21 268.21 756.01 -64.52 1122.26 914.51 22.72
TAX 46.40 72.85 -36.31 152.17 194.18 -21.63 288.82 195.04 48.08
Deferred Tax 6.25 8.25 -24.24 16.10 19.09 -15.66 25.05 27.83 -9.99
PAT 157.00 222.83 -29.54 116.04 561.83 -79.35 833.44 719.47 15.84
Equity 368.81 364.37 1.22 368.81 364.37 1.22 364.37 364.37 0.00
PBIDTM(%) 16.33 22.19 -26.44 15.56 20.06 -22.46 20.59 20.75 -0.78

Acutaas Chemicals Share Price

2361.75 16.10 (0.69%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×